Physis Pharma

Physis Pharma appears to be a small private pharmaceutical company, but public information about its operations, pipeline, and products is extremely limited. The strongest evidence for the company’s existence is third-party business registry data listing Physis Pharma or Physis Pharmaceuticals as a pharmaceutical business, and a 2022 Statera Biopharma announcement identifying Satish Chandran as CEO of Physis Pharma, Inc. Based on the available evidence, it is a healthcare-related company, but there is insufficient public disclosure to characterize a defined drug pipeline, technology platform, or therapeutic focus with confidence. The company does not appear to be publicly traded, and no verified acquisition, financing, or partnership history was found in broadly accessible sources. This profile should therefore be treated as a low-confidence entity record with sparse public-domain data.